Page last updated: 2024-08-21

isoxazoles and Parkinsonian Disorders

isoxazoles has been researched along with Parkinsonian Disorders in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Afify, EA; El-Ganainy, SO; El-Sayed, NS; Gowayed, MA; Matar, NA1
Murata, M; Nambu, A; Sano, H1
Hirayasu, Y; Odawara, T; Shiozaki, K; Togo, T1
Araki, T; Kasahara, J; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yano, R; Yokoyama, H2
Choudhury, ME; Kubo, M; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H1
Huang, YC; Liang, CS; Yang, FW1

Other Studies

7 other study(ies) available for isoxazoles and Parkinsonian Disorders

ArticleYear
The α7 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: Role of JAK2/NF-κB/GSk3β/ TNF-α pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 148

    Topics: Animals; Dopaminergic Neurons; Glycogen Synthase Kinase 3 beta; Hypokinesia; Isoxazoles; Janus Kinase 2; Neuroinflammatory Diseases; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Phenylurea Compounds; Random Allocation; Rats; Tumor Necrosis Factor-alpha

2022
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
    Journal of neurochemistry, 2015, Volume: 134, Issue:2

    Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic Neurons; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Zonisamide

2015
Administration of zonisamide in three cases of dementia with Lewy bodies.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:3

    Topics: Aged; Antiparkinson Agents; Caregivers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Lewy Body Disease; Middle Aged; Parkinsonian Disorders; Zonisamide

2010
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Metabolic brain disease, 2010, Volume: 25, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide

2010
Zonisamide attenuates MPTP neurotoxicity in marmosets.
    Journal of pharmacological sciences, 2010, Volume: 114, Issue:3

    Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Male; MPTP Poisoning; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra; Tyrosine 3-Monooxygenase; Zonisamide

2010
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
    Metabolic brain disease, 2010, Volume: 25, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide

2010
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5

    Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Parkinsonian Disorders; Psychotic Disorders; Pyrimidines; Substance Withdrawal Syndrome; Syndrome

2012